Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

---

Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma

Oncology and Translational Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Abstract Hepatocellular carcinoma (HCC) is a lethal malignancy. For many years, chemotherapeutic regimens have served as the foundation of systemic therapies for advanced HCC despite their limited efficacy and significant adverse effects. In recent decades, novel such immunotherapy targeted therapy profoundly transformed management. Although some patients with exhibit dramatically improved outcomes, therapy, either monotherapy or in combination, remains limited. Numerous trials indicated that locoregional therapies, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), radioembolization (TARE), may synergize to enhance treatment. However, further studies are required optimize these combination regimens. contrast, curative treatments, surgical resection, liver transplantation, local ablation, typically recommended early-stage HCC. treatments achieved an impressive median overall survival (OS) exceeding 60 months, more than half experience recurrence within 5 years. Consequently, development effective perioperative neoadjuvant adjuvant urgently needed reduce incidence metastasis. It provides comprehensive overview advances HCC, well immunotherapies early Additionally, emerging clinical trial designs future investigations into management critically analyzed.

Language: Английский

---

Liver resection for hepatocellular carcinoma with vascular invasion: Current insights and future perspectives

Oncology and Translational Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Abstract The role of liver resection (LR) in patients with hepatocellular carcinoma (HCC) vascular invasion (VI) remains controversial due to the inconsistent survival outcomes reported across different studies. In recent years, breakthroughs targeted therapy and immunotherapy for treatment advanced HCC, attempts improve surgical HCC VI through neoadjuvant or adjuvant have become an important research focus. This article reviewed relevant literature published years systematically analyzed studies regarding LR their outcomes. Based on previous studies, exhibits systemic characteristics. Despite use various methods resect tumor attempt efficacy by expanding extent LR, improving has been problematic. Scientifically determining while fully preserving function, combining local therapies before after surgery, exploring more effective are further VI.

Language: Английский

---

Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(14)

Published: April 9, 2025

Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related mortality worldwide. A substantial proportion patients are diagnosed with advanced or intermediate-advanced stage disease at presentation and often ineligible for curative surgery. The mainstay treatment this unique who have a liver-limited but unresectable due to large tumor burden, number lesions technical difficulties, traditionally been locoregional therapies. However, response has not satisfactory in majority patients. With advent immune therapies remarkable progress it made over past decade, management HCC undergone paradigm change. Till 2020, sorafenib, multi-targeted inhibitor vascular endothelial growth factor, platelet-derived factor rapidly accelerated fibrosarcoma was approved therapy. since 2021, nine more drugs approved, based on studies showing improved survival advanced-stage challenge clinicians face now determine best choice/combination available achieve long-term success while maintaining preserved liver function. In light emerging literature concerning therapies, including relevant randomized controlled trial by Han et al, editorial aims review currently strategies HCC.

Language: Английский

---

Adjuvant sintilimab effective in high-risk HCC

Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(3), P. 168 - 168

Published: Feb. 5, 2024

Language: Английский

---